ADRB2 and non-small cell lung carcinoma: NSCLC cell treatment with GABA blocked β-AR signaling and cell proliferation while the exposure of NSCLC cells to nicotine resulted in the downregulation of GABA synthesis, an effect reversed by cell co-treatment with the α4β2nAChR antagonist NDNI [23].